Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.59 |
| ▸ | HTR2A | P28223 | 12/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957865 | 0.83 | KCNH2 (0.42) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL29746979 | 0.82 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL3124150 | 0.82 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL3130662 | 0.81 | MCL1 (0.53) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL15073262 | 0.81 | FFAR4 (0.43) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL22957698 | 0.81 | SLC6A4 (0.56) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL22957885 | 0.79 | SLC6A4 (0.39) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL13361474 | 0.78 | SLC6A4 (0.40) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL15118586 | 0.78 | KCNH2 (0.50) | SLC6A4HTR2AKCNH2SLC6A3 | |
| SCHEMBL24459258 | 0.77 | MPO (0.41) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION | 2021-06-29 | — | — | US | disclosed |
| US-20190169194-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2019-06-06 | — | — | US | disclosed |
| US-10017512-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017512-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK2, NTRK3, NTRK1 | SLC6A4 1221/4885HTR2A 2150/4885KCNH2 3359/4885 |
| US-10017512-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | SLC6A4 1715/4885HTR2A 2952/4885KCNH2 3542/4885 |
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | SLC6A4 1715/4885HTR2A 2952/4885KCNH2 3542/4885 |
| US-20190169194-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK3, NTRK2, NTRK1 | SLC6A4 1715/4885HTR2A 2952/4885KCNH2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.